Research Topics
| Wt CreasmanSummaryAffiliation: Medical University of South Carolina Country: USA Publications
|
Detail Information
Publications
Breast cancer: the role of hormone therapyWilliam T Creasman
Department of Obstetrics and Gynecology, University Midlife Women s Health, Medical University of South Carolina, 1280 Johnnie Dodds Boulevard, Mt Pleasant, SC 29464, USA
Semin Reprod Med 23:167-71. 2005..The WHI-E only study actually notes a 23% reduction in breast cancer compared with the placebo. It would appear from a review of the literature that if there is an increased risk for breast cancer with E or E + P, it is minimal...- Cancer and pregnancyW T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA
Ann N Y Acad Sci 943:281-6. 2001..Invasive cancer management is dependent on gestational age of the fetus. Pregnancy affords an excellent opportunity to screen for cervical neoplasia... - Hormone replacement therapy after cancersWilliam T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Street, PO Box 250619, Charleston, SC 29425, USA
Curr Opin Oncol 17:493-9. 2005..With clear-cut evidence of this relation, is there evidence to suggest a role for replacement therapy in women who have been treated for endometrial cancer?.. 
The current status of lymphadenectomy in the management of endometrial cancerW T Creasman
Medical University of South Carolina, Department of Obstetrics and Gynecology, Charleston, SC 29425, USA
Womens Health (Lond Engl) 7:33-5. 2011..Approximately 3000 physicians from all geographic areas attended and heard presentations covering all aspects of gynecologic cancer...- Vaginal cancersWilliam T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
Curr Opin Obstet Gynecol 17:71-6. 2005..Vaginal neoplasia is one of the rarest of malignancies. Intraepithelial lesions are usually first identified by an abnormal Pap smear in a woman without a cervix. Surgery or ablation of the epithelium is usually highly successful... - Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometriumWilliam T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
Gynecol Oncol 95:593-6. 2004..The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer... - Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?William T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
Gynecol Oncol 92:525-9. 2004..To determine whether lymph vascular space involvement (LVSI) in women with early cervical carcinoma is an independent prognostic factor... - Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignanciesCharles N Landen
Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Boulevard, 634 CSB, Charleston, SC 29425, USA
Am J Obstet Gynecol 188:1174-6. 2003..This study was undertaken to compare the presence of cyclooxygenase-2 (COX-2) levels between normal and malignant cervix, endometrium, and ovary... - Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancerSubbi P Mathur
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
Gynecol Oncol 91:486-93. 2003.... - The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinomaEmma C Batchelor
Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
Eur J Obstet Gynecol Reprod Biol 141:163-8. 2008.... - Controversies surrounding lymphadenectomy and postoperative radiotherapy in the treatment of carcinoma of the endometriumMatthew F Kohler
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
Future Oncol 4:379-87. 2008.... - Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]Subbi P Mathur
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 634, Charleston, SC 29425, USA
Gynecol Oncol 98:467-83. 2005.... - Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology groupGary L Eddy
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mercer University School of Medicine, 840 Pine Street, Suite 760, Macon, GA 31201, USA
Gynecol Oncol 106:362-9. 2007..Adjuvant radiation therapy was prescribed for specific surgical/pathological risk factors for both regimens... - Estrogen and cancerWilliam T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina 29412, USA
Gynecol Oncol 86:1-9. 2002 - How valid are current cervical cancer prognostic factors that are used to recommend adjunctive radiation therapy after radical surgery?William T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA
Am J Obstet Gynecol 201:260.e1-3. 2009..When the published data were evaluated, the authors' conclusions were questioned. The choice of prognostic factors does not seem appropriate based on the data that were presented... - WHI: Now that the dust has settled: a commentaryWilliam T Creasman
Department of Obstetrics and Gynecology, Medical University of South Carolina, USA
Am J Obstet Gynecol 189:621-6. 2003 - Should symptomatic menopausal women be offered hormone therapy?Rogerio A Lobo
Columbia University, Columbia University Medical Center, New York, NY, USA
MedGenMed 8:1 p preceding 35. 2006..Hormone therapy should be individualized for symptomatic women. This involves tailoring the regimen and dose to individual needs... - Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group studySteven C Plaxe
Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
Gynecol Oncol 84:32-5. 2002..Due to its unique mechanism of action and preclinical activity against hypoxic and noncycling cells, PZA should be considered for evaluation in combination with other active agents... - History of the FIGO cancer staging systemFranco Odicino
Department of Obstetrics and Gynecology, Gynecologic Oncology, University of Brescia, Brescia, Italy
Int J Gynaecol Obstet 101:205-10. 2008..This paper reviews the history of the International Federation of Gynecology and Obstetrics (FIGO) cancer staging system, how it was developed, and why... 
Should symptomatic menopausal women be offered hormone therapy?Rogerio A Lobo
Columbia University, Columbia University Medical Center, New York, NY, USA
MedGenMed 8:40. 2006..Hormone therapy should be individualized for symptomatic women. This involves tailoring the regimen and dose to individual needs...